Erratum: Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland (Applied Health Economics and Health Policy (2013) 11 (457-469) DOI 10.1007/s40258-013-0044-y);Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland

Applied Health Economics and Health Policy

Volumn 11, Issue 5, 2013, Pages 457-469

  Lee, Dawn ^a   Thornton, Patrick ^b   Hirst, Alexander ^a   Kutikova, Lucie ^c   Deuson, Robert ^c   Brereton, Nic ^a  

^a BRESMED   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; ELTROMBOPAG; GLUCOCORTICOID; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; STEROID; THROMBOPOIETIN RECEPTOR;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CHRONIC DISEASE; CHRONIC IMMUNE THROMBOCYTOPENIA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEALTH SURVEY; HOSPITALIZATION; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MORTALITY; OFF LABEL DRUG USE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RISK; SPLENECTOMY; STATISTICAL MODEL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BENZOATES; CHRONIC DISEASE; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEMORRHAGE; HUMANS; HYDRAZINES; IMMUNOGLOBULINS, INTRAVENOUS; IRELAND; MALE; MIDDLE AGED; PLATELET COUNT; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 84886870279     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0066-5     Document Type: Erratum

References (72)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an International Working Group. Blood. 2009;113:2386-93.
2. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86.
3. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174-80.
4. Marieke Schoonen W, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145(2):235-44.
5. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150-4.
6. Khellaf M, Le Moine JG, Poitrinal P, Francesconi C, Haddad A, Bierling P, et al. Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis. Ann Hematol. 2011;90(4):441-6.
7. Tarantino MD, Mathias SD, Snyder CF, Isitt JJ, Gernsheimer T, Young J. Impact of ITP on physician visits and workplace productivity. Curr Med Res Opin. 2010;26(2):319-28.
8. Aledort LM, Lyons RM, Okano G, Leveque J. The clinical and direct medical cost burden of splenectomy among managed care patients with chronic immune thrombocytopenic purpura (ITP). ASH Annual Meeting Abstracts. 2006;108(11):5536.
9. Danese MD, Lindquist K, Gleeson M, Deuson R, Mikhael J. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol. 2009;84(10):631-5.
10. Amgen B.V. Nplate® summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000942/WC500039537.pdf (Accessed 11 May 2013).
11. GlaxoSmithKline. Revolade summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001110/WC500089964.pdf (Accessed 25 Oct 2011).
12. Health Information and Quality Authority (HIQA). Guidelines for the economic evaluation of health technologies in Ireland (Appendix 4); 2010. http://www.hiqa.ie/publication/guidelines-economic-evaluation-health- technologies-ireland (Accessed 8 July 2012).
13. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
14. Harrington J, Perry IJ, Lutomski J, et al. SLAN 2007: survey of lifestyle, attitudes and nutrition in Ireland. Dietary habits of the Irish population, Department of Health and Children. Dublin: The Stationery Office; 2008.
15. Kuter DJ, Bussel JB, Newland A, Wasser JS, Lyons RM, George JN, et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study (ASH Annual Meeting Abstracts). Blood. 2010;116(21):68.
16. Amgen (Europe) GmbH. Idiopathic thrombocytopenia purpura, Docscan & Physician Connect Survey; 2008 (data on file).
17. O'Keeffe D. Midwestern Regional Hospital, Limerick, Ireland; Thornton, P, Beaumont Hospital, Ireland (Personal Communication), February 2012.
18. Cooper KL, Fitzgerald P, Dillingham K, Helme K, Akehurst R. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. Int J Technol Assess Health Care. 2012;28(3):249-58.
19. Saleh MN, Cheng G, Bussel JB, Burgess P, Bakshi K, Brainsky A, et al. Long-term safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP): report of up to 5.5 years of treatment in EXTEND. Blood (ASH Annual Meeting Abstracts). 2012;120(21):2198.
20. Latimer N. National Institute for Health and Clinical Excellence, Decision Support Unit technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient level data. 2011 (updated 2013). http://www.nicedsu.org.uk (Accessed 13 May 2013).
21. Weitz I, Sanz MA, Henry D, Schipperus M, Godeau B, Northridge K, et al. A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28(5):789-96.
22. Anon. Irish life table no. 15, 2005-2007. Central Statistics Office, Ireland. http://www.cso.ie/en/newsandevents/pressreleases/2009pressreleases/ irishlifetableno152005-2007/ (Accessed 11 Dec 2012).
23. Szende A, Brazier J, Schaefer C, Deuson R, Isitt JJ, Vyas P. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. Curr Med Res Opin. 2010;26(8):1893-903.
24. McNamara RL, Lima JA, Whelton PK, Powe NR. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann Int Med. 1997;127(9):775-87.
25. Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14(1):90-6.
26. Wadenvik H, Steurer M, Janssens A, et al. Romiplostim for the treatment of adults with primary immune thrombocytopenia (ITP) in routine clinical practice - interim results from a large, European, observational study [abstract no. 0611]. Haematologica. 2011;97(S1):252.
27. Anon. Monthly Index of Medical Specialities (December). Haymarket Group; 2011.
28. Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. Int J Hematol. 2011;94(1):71-80.
29. Michel M, te Boekhorst PA, Janssens A, Pabinger-Fasching I, Sanz MA, Nie K, et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology. 2011;16(5):274-7.
30. Pullarkat VA, Gernsheimer TB, Wasser JS, Newland A, Guthrie TH Jr, de Wolf JT, et al. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). Am J Hematol. 2009;84(8):538-40.
31. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161-71 (Erratum in: Blood. 2009;113:4822).
32. Miyazaki K, Shirasugi Y, Ando K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R. An open-label extension study evaluating the safety and efficacy of up to 3.5 years of romiplostim in thrombocytopenic Japanese patients with chronic immune thrombocytopenic purpura (ITP). Haematologica. 2011;96(s2):229.
33. Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Quebec, Canada. J Med Econ. 2013;16(2):318-26.
34. Chiche L, Lefrere F, Chulikavit M, et al. Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia (ITP) in France. Value Health. 2011;14(7):A415.
35. Brosa M, Arocho R, Gutierrez L, et al. A pharmacoeconomic evaluation of romiplostim (NPLATE) for the treatment of chronic immune thrombocytopenia (ITP) (Abstract PSY425). Value Health. 2010;13(7):A464.
36. Brah S, Chiche L, Fanciullino R, Bornet C, Mancini J, Schleinitz N, et al. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Ann Hematol. 2012;91(2):279-85.
37. Lam MS. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. J Oncol Pharm Pract. 2010;16(2):89-103.
38. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549-54.
39. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
40. Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Crit Rev Oncol Hematol. 2008;65(1):21-31.
41. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232-9.
42. Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
43. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930-3.
44. Vianelli N, Valdre L, Fiacchini M, de Vivo A, Gugliotta L, Catani L, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica. 2001;86(5):504-9.
45. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Int Med. 2004;140(2):112-20.
46. Bouroncle BA, Doan CA. Treatment of refractory idiopathic thrombocytopenic purpura. JAMA. 1969;207(11):2049-52.
47. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223-8.
48. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60-4.
49. Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353-7.
50. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19-25.
51. Zver S, Zupan IP, Cernelc P. Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure. Int J Hematol. 2006;83(3):238-42.
52. Peng J, Liu C, Liu D, Ren C, Li W, Wang Z, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood. 2003;101(7):2721-6.
53. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114(1):121-5.
54. Robak T, Salama A, Kovaleva L, Vyhovska YI, Davies S, Mazzucconi MG, et al. Efficacy and safety of a new intravenous immunoglobulin product in patients with chronic immune thrombocytopenic purpura. ASH Annual Meeting Abstracts. 2007;110(11):1307.
55. Julia A, Kovaleva L, Alberca I, Hernandez F, Loria S, Sandoval V, et al. Study on the efficacy and safety of IGIV3I Grifols (human intravenous immunoglobulin) in patients diagnosed with chronic immune thrombocytopenic purpura. ASH Annual Meeting Abstracts. 2006;108(11):3956.
56. Milligan D, Eden A, Sklenar I, Adams C, Andresen I, Bender K. Therapy of patients with chronic immune thrombocytopenic purpura (ITP): efficacy, tolerability, and safety of a new liquid intravenous immunoglobulin (Abstract 485). Hematol J. 2004;5 (suppl.):S168.
57. Unsal C, Gürkan E, Güvenç B, et al. Anti-D and intravenous immunoglobulin treatments in chronic idiopathic thrombocytopenic purpura. Turkish J Haematol. 2004;21(1):27-32.
58. Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost. 2004;91(4):771-8.
59. Wolf HH, Davies SV, Borte M, Caulier MT, Williams PE, Bernuth HV, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang. 2003;84(1):45-53.
60. Colovic M, Dimitrijevic M, Sonnenburg C, Suvajdzic N, Donfrid M, Bogdanovic A. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J. 2003;4(5):358-62.
61. Pugina SA, Evdokimova NM, Rastorguev GG, Samoilova OS, Sorokina IV, Sidnev GV, et al. Treatment of idiopathic thrombocytopenic purpura in adults: efficacy of domestic intravenous immunoglobulin in immune thrombocytopenia. Ter Arkh. 1999;71(8):50-4.
62. Altintop L, Albayrak D. Oral high-dose methylprednisolone and intravenous immunoglobulin treatments in adult chronic idiopathic thrombocytopenic purpura. Am J Hematol. 1997;56(3):191-2.
63. Jacobs P, Wood L, Novitzky N. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. Am J Med. 1994;97(1):55-9.
64. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood. 1993;82(5):1415-21.
65. Leibl H, Varga G, Volkova Z, Gasztonyi Z, Hlusi A, Mayer J, et al. Efficacy and safety of a new intravenous immunoglobulin in adult subjects with chronic idiopathic thrombocytopenic purpura. ASH Annual Meeting Abstracts. 2005;106(11):3984.
66. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40.
67. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89(8):2689-700.
68. Casemix Ireland. Ready Reckoner 2011, National Casemix Program, Health Service Executive. http://www.casemix.ie (Accessed 20 Jan 2012).
69. Anon. Mater hospital cost, 2006. Inflated to November 2011 costs with the health inflator derived from central statistics office, Ireland.
70. National Health Service. National schedule of reference costs 2009-10 for NHS trusts. http://data.gov.uk/dataset/nhs-reference-costs-2009-10 (Accessed 2 Jan 2012).
71. National Centre for Pharmacoeconomics Ireland. Personal Communication; 2012.
72. National Centre for Pharmacoeconomics. Cost-effectiveness of eltrombopag (Revolade) for the treatment of chronic immune thrombocytopenic purpura (ITP). http://www.ncpe.ie/wp-content/uploads/2012/03/Summary-for-Thrombocytopenic- purpura.pdf (Accessed 13 May 2013).